Clinical investigators provide concise comments on the projected utility of cabozantinib and MDV3100 in the treatment algorithm for prostate cancer, therapeutic options subsequent to the administration of sipuleucel-T, quality of life with docetaxel and cabazitaxel and use of growth factors when administering cabazitaxel. Featuring perspectives from Drs Robert Dreicer, Daniel J George, Gary R Hudes, Philip Kantoff, Christopher J Logothetis, Daniel P Petrylak, A Oliver Sartor and Nicholas J Vogelzang.